Citius Oncology annual shares outstanding
2021
2022
2023
2024
2025
Citius Oncology Shares Outstanding History (CTOR)
Citius Oncology reported 83.5M shares outstanding at the end of fiscal 2025.
View full Citius Oncology company overviewCitius Oncology annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | 83.5M | 12.0M | +16.72% |
| 2024 | 2024-09-30 | 71.6M | 69.2M | +2956.49% |
| 2023 | 2023-12-31 | 2.3M | −75,000 | −3.10% |
| 2022 | 2022-12-31 | 2.4M | 0 | 0.00% |
| 2021 | 2021-12-31 | 2.4M | — | — |
Citius Oncology quarterly shares outstanding
Q4.21
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | 105.8M | 34.2M | +47.81% |
| Q2 2026 | 2026-03-31 | 93.0M | 21.4M | +29.95% |
| Q1 2026 | 2025-12-31 | 84.8M | 13.2M | +18.51% |
| Q4 2025 | 2025-09-30 | 83.5M | 12.0M | +16.72% |
| Q3 2025 | 2025-06-30 | 71.6M | 69.2M | +2956.49% |
| Q2 2025 | 2025-03-31 | 71.6M | 69.2M | +2956.49% |
| Q1 2025 | 2024-12-31 | 71.6M | 69.2M | +2956.49% |
| Q4 2024 | 2024-09-30 | 71.6M | 69.2M | +2956.49% |
| Q2 2024 | 2024-06-30 | 2.3M | −75,000 | −3.10% |
| Q1 2024 | 2024-03-31 | 2.3M | −75,000 | −3.10% |
| Q4 2023 | 2023-12-31 | 2.3M | −75,000 | −3.10% |
| Q3 2023 | 2023-09-30 | 2.3M | 616,000 | +35.71% |
| Q2 2023 | 2023-06-30 | 2.4M | 0 | 0.00% |
| Q1 2023 | 2023-03-31 | 2.4M | — | — |
| Q4 2022 | 2022-12-31 | 2.4M | — | — |
| Q3 2022 | 2022-09-30 | 1.7M | — | — |
| Q4 2021 | 2021-12-31 | 2.4M | — | — |
Citius Oncology shares outstanding trends
Across the available reported history, Citius Oncology's shares outstanding moved from 71.6M to 83.5M, a change of 12.0M. The latest reported quarter, Q3 2026, shows 105.8M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Citius Oncology filings at SEC.gov ↗